Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec;17(12):e011592.
doi: 10.1161/CIRCHEARTFAILURE.124.011592. Epub 2024 Nov 25.

Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction

Jason F Goldberg  1   2   3 , Xin Tian  3   4 , Ann Bon  5 , Yifei Xu  4 , Eleanor Gerhard  6 , Ruth Brower  3   4 , Moon Kyoo Jang  3   4 , Hyesik Kong  3   4 , Temesgen E Andargie  3   4 , Woojin Park  4 , Samer S Najjar  3   7 , Inna Tchoukina  3   8 , Keyur B Shah  3   8 , Steven Hsu  3   9 , Maria E Rodrigo  3   10 , Charles Marboe  3   11 , Gerald J Berry  3   12 , Hannah A Valantine  3   12 , Palak Shah  1   3   13 , Sean Agbor-Enoh  3   4   9
Affiliations
Multicenter Study

Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction

Jason F Goldberg et al. Circ Heart Fail. 2024 Dec.

Abstract

Background: Heart transplant recipients with donor-specific antibodies (DSAs) have an increased risk for antibody-mediated rejection. However, many patients with graft dysfunction and DSA do not have evidence of antibody-mediated rejection by endomyocardial biopsy (EMB).

Methods: Participants from this prospective, multicenter study underwent serial EMB, echocardiogram, DSA, and donor-derived cell-free DNA evaluations. Outcomes were defined as pAMR+ (pAMR≥1) or DSA+/left ventricle (LV) dysfunction (DSA presence+LVEF drop ≥10% to an LVEF≤50%). Cox regression evaluated the association between antibody-mediated rejection categories and death or sustained (for 3 months) reduction of LVEF to <50%.

Results: Two hundred sixteen patients (29% women, 39% Black race, median age 55 [interquartile range, 47-62] years) had 1488 EMB, 2792 DSA, 1821 echocardiograms, and 1190 donor-derived cell-free DNA evaluations. DSAs were present in 86 patients (40%). Fourteen patients had isolated pAMR+ episodes and 8 patients had isolated DSA+/LV dysfunction episodes; 2 patients had pAMR+ and then subsequently DSA+/LV dysfunction with pAMR+. Median %dd-cfDNA was significantly higher at diagnosis of pAMR+ (0.63% [interquartile range, 0.23-2.0]; P=0.0002), or DSA+/LV dysfunction (0.40% [interquartile range, 0.36-1.24]; P<0.0001), compared with patients without these outcomes (0.01% [interquartile range, 0.0001-0.10]). Both pAMR+ and DSA+/LV dysfunction were associated with long-term clinical outcome of death (n=18) or prolonged LV dysfunction (n=10): pAMR+ (hazard ratio, 2.8 [95% CI, 1.03-7.4]; P=0.043); DSA+/LV dysfunction (hazard ratio, 26.2 [95% CI, 9.6-71.3]; P<0.001); composite of both definitions (hazard ratio, 6.5 [95% CI, 2.9-14.3]; P<0.001). Patients who developed pAMR+ or DSA+/LV dysfunction within the first 6 months of transplant were more likely to die within 3 years posttransplant (hazard ratio, 3.9 [95% CI, 1.03-14.6]; P=0.031).

Conclusions: Expanding the characterization of antibody-mediated rejection to include patients with DSA and concurrent allograft dysfunction identified DSA+ patients at risk for death and prolonged LV dysfunction.

Keywords: antibodies; biomarkers; cell-free nucleic acids; heart transplantation.

PubMed Disclaimer

Conflict of interest statement

Dr Shah performed unrelated grant support paid to the institution from Merck, Bayer, Roche, and Abbott. He performed consulting for Natera, Merck, Ortho Clinical Diagnostics, and Procyrion. The other authors report no conflicts.

Comment in

  • Antibody-Mediated Rejection: Beyond the Biopsy.
    Stempien-Otero A, Minami E. Stempien-Otero A, et al. Circ Heart Fail. 2024 Dec;17(12):e012438. doi: 10.1161/CIRCHEARTFAILURE.124.012438. Epub 2024 Nov 25. Circ Heart Fail. 2024. PMID: 39584291 No abstract available.

Similar articles

See all similar articles

Cited by

References

    1. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match. J Hear Lung Transplant. 2019;38:1056–1066. - PMC - PubMed
    1. Bayliss J, Bailey M, Leet A, Stein AN, Thomson NM, McLean CA. Late Onset Antibody-Mediated Rejection and Endothelial Localization of Vascular Endothelial Growth Factor Are Associated With Development of Cardiac Allograft Vasculopathy. Transplantation. 2008;86:991–997. - PubMed
    1. Fedrigo M, Gambino A, Tona F, Torregrossa G, Poli F, Benazzi E, Frigo A, Feltrin G, Toscano G, Caforio AP, Iliceto S, Valente M, Thiene G, Gerosa G, Angelini A. Can C4d Immunostaining on Endomyocardial Biopsies Be Considered a Prognostic Biomarker in Heart Transplant Recipients? Transplantation. 2010;90:791–798. - PubMed
    1. Crespo-Leiro MG, Veiga-Barreiro A, Doménech N, Paniagua MJ, Piñón P, González-Cuesta M, Vázquez-Martul E, Ramirez C, Cuenca JJ, Castro-Beiras A. Humoral Heart Rejection (Severe Allograft Dysfunction with no Signs of Cellular Rejection or Ischemia): Incidence, Management, and the Value of C4d for Diagnosis. Am J Transplant. 2005;5:2560–2564. - PubMed
    1. Moseley EL, Atkinson C, Sharples LD, Wallwork J, Goddard MJ. Deposition of C4d and C3d in cardiac transplants: A factor in the development of coronary artery vasculopathy. J Hear Lung Transplant. 2010;29:417–423. - PubMed

Publication types

MeSH terms

LinkOut - more resources